The collaboration will create an end-to-end service for the development and commercialisation of biosimilars and novel antibody therapies, by integrating Charles River’s discovery, pre-clinical and analytical testing with Prestige’s development and Contract Development and Manufacturing Organisation (CDMO) capabilities.
Additionally, the collaboration initiates a joint global business development strategy. Under the terms of the MOU, Charles River will refer clients requiring biopharmaceutical process development and manufacturing to Prestige, while Prestige will connect clients in need of early-stage discovery, preclinical toxicology and bioanalytical services to Charles River. The companies plan to utilise joint marketing initiatives to increase their global presence.
In 2023, Prestige Biologics entered into a non-binding MOU with a Dr. Reddy’s Laboratories subsidiary for the manufacturing, packaging and distribution of Dr. Reddy’s extensive biopharmaceutical pipeline in South Korea.